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ABSTRACT Keratin 8 (K8) and keratin 18 (K18) are
intermediate ifiament proteins normally expressed in simple
epithellal tissues and persistently expressed in a wide variety of
carcinomas. Ectopic expression of K8 and K18 occurs in some
epidermal and murine skin carcinomas induced by chemical
carcinogenesis or oncogenic ras expression. We show here that
K18 is a direct target of the Ras signal transduction pathway,
by demonstrating that activated Ha-Ras, as well as activated
Src, Lck, or Raf, stimulates the transcription of K18. This
activation is mediated by an enhancer element containing
essential and closely spaced Fts and AP-1 transcription factor
binding sites. Oncogene activation of K18 transcription pro-
vides a molecular explanation for the persistent and sometimes
unexpected expression of K18 in such a wide variety of tumors.
Keratin intermediate filament expression is a useful charac-
teristic to distinguish carcinomas from other types of cancer.
The keratin 18 (K18) gene codes for a type I intermediate
filament protein found primarily in a variety of single-layered
or simple epithelial tissues (1, 2). K18 and its coexpressed
complementary subunit, keratin 8 (K8), are persistently
expressed, often at elevated levels, in a wide variety of
carcinomas derived from internal epithelia including liver,
pancreas, intestine, colon, mammary gland, and the uterine
and urinary tracts (3-7). Ectopic expression of K8 and K18
occurs in some human epidermal carcinomas (8), murine skin
carcinomas induced by chemical carcinogenesis or oncogenic
ras expression (9, 10), and highly metastatic melanoma cells
(11). Furthermore, differences in the reactivity ofK18 mono-
clonal antibodies with the invasive front of human transi-
tional carcinomas (6) and the implication of K8 and K18
filaments in the invasive behavior of cultured cells (12)
suggest that K8 and K18 may be functionally important in
tumor cell behavior.
Expression of K18 is dependent upon a complex transcrip-
tional enhancer element located within the first intron of the
gene (13). Previous studies identified an important AP-1
transcription factor binding site within a conserved 47-bp
sequence of this enhancer that mediates transactivation by
members of the Jun and Fos families. Here we report the
identification of a second transcription factor binding site
within the conserved portion of the K18 enhancer that is
recognized by members of the Ets family of transcription
factors. We show that Ets and AP-1 activate transcription of
the K18 gene additively through their respective binding sites
situated 9 bp apart. Furthermore, we show that the combi-
nation of the Ets and AP-1 sites forms an oncogene-
responsive regulatory element that mediates transcriptional
activation by a number ofnonnuclear oncogenes, all ofwhich
activate the Ras signal transduction pathway.
Cellular transformation results in the altered transcription
of a number of cellular genes, some of which are likely
important for tumor growth, progression, invasion, and me-
tastasis (14, 15). A wide variety of nonnuclear oncogenes,
including activated receptor tyrosine kinases, nonreceptor
tyrosine kinases, guanine nucleotide binding proteins, and
serine/threonine kinases, can activate target genes through a
limited number ofregulatory elements (14-18). Several ofthe
genes activated by the Ras signal transduction pathway
require the concerted action of closely spaced binding sites
for the Ets and AP-1 transcription factors (16-18). Activation
of genes through Ets and AP-1 sites appears essential for
oncogenesis because both Ras-induced transcriptional acti-
vation and cellular transformation are blocked by dominant
inhibitory mutants of Jun, Fos, or Ets (19-21). The identifi-
cation of genes activated by oncogenes will likely provide
multiple targets essential for different aspects of tumor cell
behavior. Furthermore, identification of the molecular mech-
anisms mediating transcriptional activation by nonnuclear
oncogenes may provide targets ofintervention through which
a large variety of activated oncogenes mediate their tran-
scriptional effects (15). The finding that many classes of
oncogenes can activate K18 expression through its oncogene-
responsive element may explain why most carcinomas con-
tinue to express this intermediate filament protein and leads
to consideration of possible functions of simple epithelial
keratins in tumors.
METHODS AND MATERIALS
Cell Culture. F9.22 mouse embryonal carcinoma cells were
cultured in Dulbecco's modified Eagle's medium (DMEM)
supplemented with 10%o (vol/vol) fetal bovine serum. NIH
3T3 cells were grown in DMEM supplemented with 10%o
(vol/vol) calf serum.
Plasmid Constructions. A 663-bp fragment ofthe first intron
of K18 was placed downstream of the 250-bp K18 proximal
promoter, chloramphenicol acetyltransferase (CAT) gene,
simian virus 40 tumor antigen intron, and polyadenylylation
signal of the previously described XKCATspA vector to
generate XKCATIs (13). A variant with a mutated Ets site
(XKCATmETS) was generated by PCR with the indicated
primers and substituted for the wild-type intron in XKCATIs
(Fig. 1). The construction of a variant with a mutated AP-1
site (XKCATmAP-1) is described elsewhere (13). The ex-
pression vector for wild-type Ras and oncogenic Ras (Ha-ras
61L) was pZIPneoSV(X)l and has been described (22). The
activated Raf expression construct was made by inserting a
truncated Rafgene (p22W, ref. 23) into the same vector. The
v-Src expression construct was made by inserting the v-src
Abbreviations: K8, human keratin 8; K18, human keratin 18; CAT,
chloramphenicol acetyltransferase.
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FiG. 1. Functional analysis ofthe Ets and AP-1 binding site within the first intron ofhuman K18. (A) Schematic diagrams ofthe CAT reporter
constructs used in transient transfection analysis. In all constructs the CAT transcription unit is followed by the simian virus 40 tumor antigen
intron (SV40sp) and polyadenylylation signals (SV4OpA) and was driven by 250 bp of 5' flanking sequence of K18. The XKCATmETS and
XKCATmAP1 vectors contain mutations of the Ets and AP-1 sites, respectively. The mutations are indicated below the wild-type sequences.
Dashes indicate unchanged residues and a dot indicates a deleted nucleotide. Uppercase type indicates identical nudeotides in mouse and human
K18 first introns. Positions ofthe PCR primers used for the construction ofthe Ets mutation are indicated. (B) Trans-activation ofthe XKCATIs
and its mutated variants XKCATmETS and XKCATmAP-1 by different members of the Ets and Jun oncogene families in P9 embryonal
carcinoma cells. CAT activity was normalized to -galactosidase activity in the same lysate of a cotransfected lacZ gene driven by the P-actin
promoter. The indicated fold activation is relative to the reporter construct alone. The basal levels of the XKCATmETS and XKCATmAP-1
vectors were typically -40% and 30%6, respectively, ofthe wild-type construction. The results shown represent averages oftwo or more separate
experiments.
gene into pLSDL (24). The activated Lck expression con-
struct is LckF505 (25). The v-Src and LckF505 expression
constructs were generously supplied by M. Kamps (Salk
Institute, La Jolla, CA).
To replace the Ets and AP-1 mutations into the context of
the whole K18 gene, two regions of the gene from positions
-314 to +505 and positions +1167 to +2400 were synthe-
sized by the PCR and joined by synthetic Xba I restriction
sites to form a deletion of663 bp ofthe first intron. A fiagment
containing the deletion was inserted into K18 via unique Xho
I and Nco I sites. Xba I restriction fiagments ofthe wild-type
first intron or its mutated variants were generated from
XKCATIs, XKCATmETS, and XKCATmAP-1 and were
inserted into the Xba I site of the deleted intron to generate
a control form ofK18 (K18In) and constructs with a mutated
Ets site (K18mETS) or mutated AP-1 site (K18mAP-1).
DNA Transfections and CAT Assays. For P9 cells, the
reporter CAT constructs (10 pg) were transfected by the
calcium phosphate precipitation method along with 2 pg of
expression vectors of the indicated trans-activators and 2 plg
ofa 0-actin-LacZ plasmid (13). When necessary, pUC9DNA
was added for a total of 20 pg of DNA per 9-cm plate.
Thirty-six hours after transfection, the cells were harvested
and CAT and f-galactosidase activities were determined as
described (13). Dishes (6 cm) of NIH 3T3 cells were trans-
fected by calcium phosphate coprecipitation of 2 pg of the
indicated reporter gene, 5 pg of the expression construct
(except 0.5 pg of v-src), and 8 pg of pUC19 carrier DNA.
Sixteen hours after the precipitate was added, the cells were
washed with phosphate-buffered saline, and the medium was
replaced with DMEM containing 0.5% calf serum. After an
additional 24 hr, the cells were harvested and the CAT
activity was determined.
RNa.e Analysis. Seven micrograms of DNA
from each K18 construct was cotransfected with 8 pg of
expression construct for wild-type (Ha-ras wt) or oncogenic
(Ha-ras 61L) Ras per 9-cm dish of cells by the calcium
phosphate precipitation method. Five micrograms of stan-
dard plasmid pMC1NeopA DNA was included in each ex-
periment to determine transfection efficiency. RNA was
purified by a single-step isolation method (26). Total RNA
was treated with RNase-free DNase I at 37°C for 60 min in the
presence of RNase inhibitor (Stratagene). RNA (20 pg) was
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In Vitro Footprinting. Analysis of the binding of recombi-
nant c-Jun and c-Ets2 DNA binding domain to the K18 intron
enhancer by DNase I protection was performed as described
(28). A DNA fragment of K18 from positions +735 to +973
was end-labeled and incubated with bovine serum albumin,
recombinant c-Jun and c-Fos purified from Escherichia coli
(gifts of T. Deng and M. Karin, University of California, San
Diego), or recombinant Ets-2 DNA binding domain and
digested with DNase I. Fragments were separated on a
sequencing gel and visualized by autoradiography.
RESULTS
Closely Spaced Ets and AP-1 Binding Sites Function in the
K18 Enhancer. A complex transcriptional enhancer within
the first intron ofK18 contains an essential AP-1 transcription
factor binding site embedded within a 47-bp sequence that is
identical in the mouse and human genes (13). Deletion and
mutagenesis analysis located a functional Ets binding site at
position +7%, 9 bp upstream of the AP-1 site in the first
intron (Fig. 1A). Deletion or mutation of two other potential
Ets binding sites at positions +703 and +1104 had no effect
on Ets transactivation (data not shown). The K18 Ets motif
differs from a similar site associated with the collagenase
promoter (17) by a single nucleotide. The K18 enhancer was
activated by either Ets or Jun family members and the effect
of combining them was additive (Fig. 1B). JunD failed to
activate the K18 reporter construction but did not interfere
with the activation by Ets (Fig. 1B). Another Ets family
member, PU.1 (29), also failed to activate the K18 enhancer
(data not shown), indicating that only a subset of Ets and
AP-1 family members are active on this enhancer element.
Mutation of the K18 Ets site abrogated transactivation by
both Ets-1 and Ets-2 and decreased transactivation by c-Jun
and JunB (Fig. 1B). Similarly, mutation of the neighboring
AP-1 site abolished transactivation by Jun and reduced
activation by Ets (Fig. 1B). The mutual reduction in activa-
tion by factors whose cognate sites were not changed sug-
gests that the Ets and Jun transcription factors may interact.
To confirm that Ets and AP-1 proteins can bind to the
expected sites in the K18 first intron, DNase I footprinting
analysis was performed on plasmid DNA containing these
sites with a recombinant c-Ets-2 DNA binding domain and
c-Jun/c-Fos proteins (Fig. 2). The Ets DNA binding domain
generated a footprint centered on the expected Ets site at nt
+7% with an internal DNase I hypersensitive site, as ob-
served in the footprint pattern of other members of the Ets
family (30, 31). Similarly, c-Jun/c-Fos bound to the expected
AP-1 site. Furthermore, genomic footprinting methods re-
vealed that the Ets binding site and AP-1 site were occupied
in K18 transgenic mouse liver, which expressed the transgene
(32), but were not occupied in nonexpressing transgenic
spleen (A.U. and R.G.O., unpublished results). These results
reinforce the views that transactivation by Ets and Jun occurs
by direct binding to the K18 sequences and that normal
expression is correlated with the occupancy of these sites.
Activation of K18 Transcription by Nonnuclear Oncogenes
Requires Both the Ets and AP-1 Sites. The close proximity and
apparent interdependence ofthe Ets and AP-1 sites within the
K18 intron enhancer resembles the oncogene-response ele-
ments found in several viral and cellular genes (15). To test
whether the closely spaced Ets and AP-1 sites in K18 are
oncogene-response elements, K18 reporter genes were co-
transfected with oncogene expression constructs (Fig. 3).
While activation by wild-type Ras was minimal, the expres-
sion of oncogenic Ras resulted in an 11-fold increase in
expression of the CAT reporter gene containing a single copy
of the K18 enhancer (XKCATIs). Mutation of either the Ets
or the AP-1 binding site abolished the activation by oncogenic
Ras. This requirement for both the Ets and AP-1 binding sites
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FIG. 2. Binding of recombinant Ets-2 and c-Jun/c-Fos to the
human K18 first intron enhancer. An end-labeled DNA fragment of
the K18 first intron (nt 735-973) was incubated with bovine serum
albumin (BSA, lanes 1-3), a combination of recombinant c-Jun and
c-Fos (lanes 4-6), or the human Ets-2 DNA binding domain (lanes
7-9) and digested with DNase I. The concentration of nuclease was
75 ng/ml (lane 1), 150 ng/ml (lane 2), 300 ng/ml (lane 3), 100 ng/ml
(lanes 4 and 7), 200 ng/ml (lanes 5 and 8), or 400 ng/ml (lanes 6 and
9). The positions of the observed AP-1 and Ets-2 footprints are
indicated to the right.
is similar to that previously found for several other oncogene
response elements (16-18). The activation by Ras was not
dependent upon the homologous K18 promoter used in these























FIG. 3. Nonnuclear oncogenes activate K18 transcription
through adjacent Ets and AP-1 sites in the enhancer. Relative
activation for each reporter (shown in Fig. 1A) in 3T3 cells was
calculated by comparing CAT activity of the reporter cotransfected
with oncogene expression constructs to the same reporter cotrans-
fected with empty expression vector. The basal level ofeach reporter
was defined as 1.0, but the basal level of the Ets and AP-1 mutants
was 3- and 9-fold lower than wild type, respectively. The results
shown are the average of at least two experiments.
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gene driven by the Herpes simplex thymidine kinase gene
promoter and the K18 intron enhancer (data not shown).
Furthermore, cotransfection experiments with XKCATIs
revealed that K18 expression is similarly induced through this
element by activated Raf, v-Src, or activated Lck (Fig. 3).
Cotransfection of the nuclear oncogeneEMA did not induce
K18 expression (data not shown). We noted that mutations in
the Ets or AP-1 sites did not completely abolish the K18
activation by Src and Lck, and it is likely that this residual
activation occurs by a pathway distinct from Ras. Src and
Lck can activate expression of a minimal promoter construct
not activated by oncogenic Ras, and high-level expression of
a dominant negative Ras (Asn-17) mutant (33) only partially
inhibits Src and Lck activation of K18 (data not shown).
Overall, these results demonstrate that the K18 enhancer
element is a target for transcriptional activation by oncogenic
Ras and other activated steps both upstream and downstream
in the Ras signal transduction pathway.
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FIG. 4. Ras-induced trans-activation of K18 and its mutated
variants K18 mETS and K18mAP-1. (A) Schematic representation of
K18 and the strategy used for introduction of the mutations in Ets and
AP-1 binding sites. At the top, a portion of K18 is represented with
exons designated as solid boxes numbered from 1 to 7. Shaded boxes
represent Alu-type repetitive elements. The region of the first intron
(positions 465-1208 relative to the major start of transcription) is
enlarged and the positions of Ets binding site (ETS) and AP-1 binding
site (AP-1) are indicated. H, HindIII; X, Xho I; Xba, Xba I; Bg, Bgl
II; B, BamHI. (B) RNase protection analysis of the products of the
indicated constructs after transient expression in NIH 3T3 cells.
Each K18 construct was cotransfected with the indicated expression
vectors. RNA was isolated and analyzed by RNase protection
analysis using simultaneous hybridization with [32P]UTP-labeled
probes for the neomycin-resistance gene and the K18 first exon (26).
The amount of RNA loaded in each lane was normalized to the
neomycin-resistance mRNA signal to facilitate direct comparison of
the K18 signals. The positions of the protected fragments are
indicated to the left. Lanes: t, 20 pg of tRNA (negative control); K,
10 pg of synthetic K18 mRNA standard; N, 5 pg of synthetic
neomycin-resistance mRNA standard. The protected fragment of the
K18 standard is slightly shorter than the expressed RNA because not
all of the 5' noncoding sequence is included in the K18 cDNA.
The Ets and AP-1 Sites Are Required for Ras Responsiveness
in the Context of the Whole K18 Gene. Because most analysis
of Ras-responsive elements has been performed with fusion
genes containing multimerized response elements, the mu-
tations of the intron Ets and AP-1 binding sites were tested
within the context of the whole K18 gene. The results of these
RNase protection experiments (Fig. 4) show that mutation of
either the Ets or AP-1 sites greatly reduces the Ras respon-
siveness of the K18 gene. These findings confirmed the
importance of the intron enhancer as the major mediator of
K18 transcriptional activation by Ras. However, in contrast
to the results of the CAT reporter genes containing the
isolated intron, the mutation of the Ets binding site did not
completely abolish the Ras activation of the whole gene. This
suggests that other K18 regulatory elements may make a
small contribution to the observed transcriptional activation
of K18 by oncogenic Ras.
DISCUSSION
The Ras signal transduction pathway provides a means of
integrating a large number of regulatory signals, some of
which may be involved in normal regulation of K18 during
development. Our results show that members of the Ets and
AP-1 transcription factor families can bind to K18 intron
enhancer sequences and that mutation of these binding sites
abrogates the transcriptional activation by the cognate tran-
scription factors. The activation of K18 by Ras, Raf, v-Src,
and Lck is dependent upon the same two sites. This suggests
that other oncogenes that activate the Ras signal transduction
pathway could similarly activate K18. Clearly, the Ets and
AP-1 binding sites of the K18 intron enhancer mediate this
activation even with a single copy of the enhancer. However,
the K18 enhancer is complex and the 47-bp conserved
sequence containing the Ets and AP-1 binding sites is not
sufficient for enhancer activity (13) nor does it support Ras
activation of a K18-CAT reporter construct (R.P., C.H., and
R.G.O., unpublished data). Thus, these regulatory elements,
when assayed within the context of the conserved region of
the enhancer, are necessary but not sufficient for the Ras
responsiveness of the K18 gene. The interaction between the
factors that bind to both sites is not clear. The decrease in
transactivation by Jun when the Ets site is mutated and the
decrease in transactivation by Ets when the Jun site is
mutated (Fig. 1) would suggest an interaction between the
two types of transcription factors. A similar dependence on
both sites for transactivation by Ras was observed. However,
the transactivation of the enhancer by both transcription
factors appears to be only additive and not synergistic as
might be expected from other examples of interacting tran-
scription factors. The mechanism of activation through these
regulatory elements remains to be determined. Oncogenic
Ras has been found to stimulate phosphorylation of the c-Jun
activation domain, which correlates with enhanced AP-1
activity (34). It remains to be determined which members of
the Ets, Jun, or Fos transcription factor families mediate the
increased activity of the Ras-responsive elements that re-
quire both Ets and AP-1 binding sites. K18 expression is
regulated by both its chromatin state (27, 35, 36) and trans-
acting transcription factors (13). While we have not detected
elevated mouse K18 expression in Ras-transformed 3T3
fibroblasts (R.P. and R.G.O., unpublished data), K18 may be
particularly stably repressed in cultured fibroblasts by its
chromatin state and by additional methylation of the gene in
cultured cells not found in tissues of mice (27, 35). Escape
from a repressive chromatin state may account for the
unusual expression of K18 in some normal tissues and
transformed cell lines (9, 10, 37, 38). As the repressed
chromatin state of K18 appears relatively stable, it is of
interest to determine whether the activation of the Ras signal
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Proc. Natl. Acad. Sci. USA 91 (1994) 877
transduction pathway increases the probability of release
from a repressive chromatin state. This reliefmay be a major
component ofthe stochastic nature ofectopic K18 expression
in nonepithelial-derived tumors and transformed cells (37,
38).
We suggest that tumors that express a variety of nonnu-
clear oncogenes may share the characteristic of an activated
Ras signal transduction pathway resulting in elevated expres-
sion of endogenous target genes through Ets and AP-1
regulatory elements. Some of these genes are likely to be
functionally important for tumor progression. The structure
of the K18 oncogene-responsive element is closely related to
that reported for two extracellular proteases, collagenase and
stromelysin, that are thought to be important to the invasive
behavior of tumor cells (17, 39). The identification of K18 as
an oncogene-responsive target reinforces the potential im-
portance of cytoskeletal elements in mediating the behavior
of carcinomas. The activation of K18 expression by Ras or
other oncogenes may be functionally important to the inva-
sive behavior of tumor cells, because K18 expression has
been correlated with increased invasiveness (6, 8, 11, 40).
Furthermore, experiments utilizing forced expression of K8
and K18 proteins suggest a possible role for these keratin
filaments in invasive motility (12). Thus, deregulated expres-
sion ofK8 and K18 may contribute to the metastatic behavior
of tumor cells.
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